Brennan M. R. Spiegel, Roger Bolus, Steven Han, Myron Tong, Eric Esrailian, Jennifer Talley, Tram Tran, Jason Smith, Hetal A. Karsan, Francisco Durazo, Bruce Bacon, Paul Martin, Zobair Younossi, Siew Hwa‐Ong, Fasiha Kanwal – 27 June 2007 – Despite the increasing realization that health‐related quality of life (HRQOL) is an important outcome in chronic HBV infection, there are no validated, disease‐targeted instruments currently available.

Ingrid Herr, Peter Schemmer, Markus W. Büchler – 27 June 2007 – Hepatocellular carcinoma (HCC) ranks among the 10 most common cancers worldwide. The fact that HCC is resistant to conventional chemotherapy and is rarely amenable to radiotherapy leaves this disease with no effective therapeutic options and a very poor prognosis. Therefore, the development of more effective therapeutic tools and strategies is much needed.

Rushang D. Patel, Brett D. Hollingshead, Curtis J. Omiecinski, Gary H. Perdew – 27 June 2007 – The aryl‐hydrocarbon receptor (AhR) is a basic helix‐loop‐helix/Per‐Arnt‐Sim transcription factor that can be activated by exogenous as well as endogenous ligands. AhR is traditionally associated with xenobiotic metabolism. In an attempt to identify novel target genes, C57BL/6J mice were treated with β‐naphthoflavone (BNF), a known AhR ligand, and genome‐wide expression analysis studies were performed using high‐density microarrays.

Koichi Matsuzaki, Miki Murata, Katsunori Yoshida, Go Sekimoto, Yoshiko Uemura, Noriko Sakaida, Masaki Kaibori, Yasuo Kamiyama, Mikio Nishizawa, Junichi Fujisawa, Kazuichi Okazaki, Toshihito Seki – 27 June 2007 – Many patients with chronic hepatitis caused by hepatitis C virus (HCV) infection develop liver fibrosis with high risk for hepatocellular carcinoma (HCC), but the mechanism underling this process is unclear.

Yangchao Chen, Marie C. Lin, Hong Yao, Hua Wang, Ai‐Qun Zhang, Jun Yu, Chee‐kin Hui, George K. Lau, Ming‐liang He, Joseph Sung, Hsiang‐fu Kung – 27 June 2007 – Enhancer of zeste homolog 2 (EZH2) has been shown to be overexpressed in hepatocellular (HCC). We investigated the potential role of EZH2 in HCC tumorigenesis and examined the usefulness of RNA interference (RNAi) targeting EZH2 as a form of HCC treatment. Lentivirus‐mediated RNAi was employed to knock‐down EZH2 expression in human hepatoma cells to study the function of EZH2 in tumorigenesis and evaluate the treatment efficacy.

Mirella Fraquelli, Cristina Rigamonti – 27 June 2007

Johannes Herkel, Michael P. Manns, Ansgar W. Lohse – 27 June 2007

Cara L. Mack – 27 June 2007

Jens H. Henriksen – 27 June 2007

Anna S. F. Lok, Brian J. McMahon – 27 June 2007